oncology, metabolomics, drug design, structural biology, cell biology
cancer cell lines, patient samples
3D structural characterization, fragment-based screening, metabolomic profiling, computational chemistry approaches, protein expression, protein purification
My group collaborates with a number of national and international researchers interested in translational pharmaceutical and clinical research. In particular, we maintain close collaborations with pharmaceutical companies and SMEs to develop novel drugs using structure-based drug design approaches. At the same time, we collaborate with clinicians located in different academic institutions and research hospitals to characterize metabolomic profiles of patients diagnosed with different oncological diseases. These projects are focused on the identification of clinically relevant biomarkers for the diagnosis, prognosis, patient monitoring and treatment evaluation.
Currently, our research focuses on the structural characterization of therapeutically relevant protein targets, the identification of inhibitors of the biological activity of those targets and metabolomics profiling by NMR. From a technical point of view, we mainly use Nuclear Magnetic Resonance (NMR) spectroscopy, both as a high resolution and screening (fragment-based) technique, in combination with other biophysical (surface plasmon resonance, circular dichroism, fluorescence spectroscopy, etc.), biochemical (molecular biology, protein chemistry, cell biology, etc.) and computational (QSAR, docking, etc.) approaches to study the 3D structure and properties of proteins, protein-protein and protein-ligand complexes, as well as metabolites in solution.
• Board member, Spanish Society of Medicinal Chemistry • Coordinator, Clinical Metabolomics Initiative, Conselleria de Sanitat, Generalitat Valenciana • Coordinator, ERA-NET “New Indigo”, TBomics: An omics approach for diagnosing tuberculosis • Reviewer, Marie Sklodowska Curie Actions, Chemistry Panel